TerminatedPhase 2NCT01061606
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Mark Einstein, MDMontefiore Medical Center - Moses Campus
- Intervention
- temsirolimus(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2010 – 2012
Study locations (20)
- Tower Cancer Research Foundation, Beverly Hills, California, United States
- City of Hope, Duarte, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- City of Hope Medical Group Inc, Pasadena, California, United States
- University of California at Davis Cancer Center, Sacramento, California, United States
- University of Connecticut, Farmington, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Morristown Memorial Hospital, Morristown, New Jersey, United States
- The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States
- Women's Cancer Care Associates LLC, Albany, New York, United States
- Beth Israel Medical Center, New York, New York, United States
- New York University Langone Medical Center, New York, New York, United States
- Saint Luke's Roosevelt Hospital Center - Roosevelt Division, New York, New York, United States
- Presbyterian-Weill Medical College, New York, New York, United States
- Mount Sinai School of Medicine, New York, New York, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01061606 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.